Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
← catalyst calendarSponsored by Disc Medicine, Inc (industry) · IRON — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
55actual
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-04 | actual | When the study began enrolling |
| Primary completion | 2025-10-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-16 | actual | The whole study's end, after follow-up |
| First posted | 2023-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Kidney Diseases
- Anemia of Chronic Kidney Disease
Interventions
- Drug: DISC-0974
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events
measured up to 145 days
Incidence of clinically abnormal vital signs
measured up to 145 days
Incidence of abnormal laboratory test results
measured up to 145 days
Incidence of clinically abnormal physical exam
measured up to 145 days
Incidence of clinically abnormal electrocardiograms
measured up to 145 days
Permalink · IRON's whole pipeline · Catalyst calendar · Every registered study · What changed